A safety checklist before initiating second-generation immunomodulating drugs for inflammatory dermatoses: a systematic review.
J Dermatolog TreatMay 4, 2026 (epub)
Clinical ResearchDermatology
Stine R Haysen, Lykke Skaarup, Simon Poulsen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined contraindications and warnings for second-generation immunomodulating drugs used in inflammatory dermatoses. It identified significant safety concerns, particularly regarding infection risks and malignancy. The review provides a safety checklist to assist clinicians in evaluating these therapies before initiation.
Key findings
- Warnings related to infections were common across most drug classes.
- Herpes zoster was noted for anti-CD20, IL-12/23i, INFi, JAKi, and TYK2i.
- Malignancy risk, including skin cancer, was mentioned for most classes except IL-23i and others.
- Serious warnings included neurological, cardiovascular, and psychiatric adverse events.
Why it matters
Clinicians need to be aware of the potential risks associated with second-generation immunomodulating drugs to ensure patient safety. A comprehensive safety checklist can streamline the evaluation process and enhance clinical decision-making.